Alemayehu Duga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alemayehu Duga has a total of 233 co-authors. Here are the top co-authors by number of shared publications:
- Nebiyu Dereje
Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia
5 shared publications - Albert Figueras
Independent Consultant, Quality and Safe Use of Medicines. Retired Professor, Department of Pharmacology, Universitat Autònoma de Barcelona, Spain
3 shared publications Jean Kaseya
Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia
3 shared publicationsLinda Härmark
The Netherlands Pharmacovigilance Center Lareb, s-Hertogenbosch, The Netherlands
3 shared publicationsTajudeen Raji
Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia
3 shared publicationsTamrat Shaweno
Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia
3 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Elsevier in Biologicals
- Vol. 96
Assessing consequences of maternal immunization on fetal outcomes - A meeting report
- 21 October 2026
- Published by Elsevier in Biologicals
- Vol. 96
Open AccessAssessing consequences of maternal immunization on fetal outcomes - A meeting report
- Open Access
- 9 October 2026
- Published by CERN in Open Research Europe
Strengthening pharmacovigilance systems through Africa-Europe collaboration: Insights from a regulatory roundtable discussion
Background Many African countries have established national pharmacovigilance (PV) centers under their medicines regulatory authorities, but multiple barriers still limit system performance. Comprehensive, well-enforced PV regulations are often lacking, and the reporting culture among healthcare professionals and patients remains weak due to limited awareness, heavy workloads, and fear of legal consequences. The limited uptake of digital tools also leads to continued reliance on paper-based reporting, undermining data management and analysis. This manuscript summarizes an Africa–Europe roundtable where regulators discussed experiences, challenges, and priorities for strengthening PV systems. Methods The Center for Medical Ethics at the University of Oslo, in collaboration with Gispen4Regulatory Science, organized an in-person, two-day Europe-Africa roundtable discussion on June 5-6, 2025, focusing on global reflections on PV. This manuscript synthesizes discussions from a high-level Africa-Europe drug regulators, researchers and policy experts on the development and integration of PV. The roundtable brought together 30 experts for a cross-regional dialogue on drug regulation. This exchange illuminated common goals and significant asymmetries in infrastructure, capacity, and policy implementation across regions. Results The event fostered critical discussions on real-world safety monitoring, regulatory practices, and differences in health systems through short, problem-focused presentations based on active research and field practice. The roundtable discussion revealed disparities in technological and infrastructural capacity, human-resource challenges and sustainability, funding stability, community and patient engagement, and the utilization of data. It also highlighted gaps in regional harmonization, and institutional models. The study also emphasized shared values, the development of mechanisms for mutual learning and coordinated approaches. Conclusion Drawing on shared experiences, participants formulated a series of actionable recommendations aimed at fostering sustainable, collaborative, and technology- supported PV systems in Africa. The insights inform future strategies for harmonization and mutual learning within global drug safety governance.
- 9 October 2026
- Published by CERN in Open Research Europe
Open AccessStrengthening pharmacovigilance systems through Africa-Europe collaboration: Insights from a regulatory roundtable discussion
Background Many African countries have established national pharmacovigilance (PV) centers under their medicines regulatory authorities, but multiple barriers still limit system performance. Comprehensive, well-enforced PV regulations are often lacking, and the reporting culture among healthcare professionals and patients remains weak due to limited awareness, heavy workloads, and fear of legal consequences. The limited uptake of digital tools also leads to continued reliance on paper-based reporting, undermining data management and analysis. This manuscript summarizes an Africa–Europe roundtable where regulators discussed experiences, challenges, and priorities for strengthening PV systems. Methods The Center for Medical Ethics at the University of Oslo, in collaboration with Gispen4Regulatory Science, organized an in-person, two-day Europe-Africa roundtable discussion on June 5-6, 2025, focusing on global reflections on PV. This manuscript synthesizes discussions from a high-level Africa-Europe drug regulators, researchers and policy experts on the development and integration of PV. The roundtable brought together 30 experts for a cross-regional dialogue on drug regulation. This exchange illuminated common goals and significant asymmetries in infrastructure, capacity, and policy implementation across regions. Results The event fostered critical discussions on real-world safety monitoring, regulatory practices, and differences in health systems through short, problem-focused presentations based on active research and field practice. The roundtable discussion revealed disparities in technological and infrastructural capacity, human-resource challenges and sustainability, funding stability, community and patient engagement, and the utilization of data. It also highlighted gaps in regional harmonization, and institutional models. The study also emphasized shared values, the development of mechanisms for mutual learning and coordinated approaches. Conclusion Drawing on shared experiences, participants formulated a series of actionable recommendations aimed at fostering sustainable, collaborative, and technology- supported PV systems in Africa. The insights inform future strategies for harmonization and mutual learning within global drug safety governance.
- 24 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (8) , 1-3
Inspiring, shaping and sustaining an African research & development agenda
- 24 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (8) , 1-3
Inspiring, shaping and sustaining an African research & development agenda
- Open Access
- 13 May 2026
- Published by Elsevier in SSRN Electronic Journal
Barriers and Facilitators of Signal Detection in African Pharmacovigilance Centres: Insights from a Multi-Country Qualitative Study
Background: Signal detection within African pharmacovigilance systems has faced multiple challenges. The contextual factors influencing signal detection and management remain underexplored. This study aimed to investigate and better understand the determinants that facilitate or hinder these processes across African pharmacovigilance systems.Methods: An explanatory qualitative design was employed, using in-depth interviews with representatives from selected National Pharmacovigilance(PV) Centers in Africa. A framework thematic analysis approach was applied to the data and synthesized using NVivo® 15 software.Findings: Twelve participants were included in the study. The framework thematic analysis generated three main themes and 13 subthemes related to signal detection and management in the African context. Major challenges included the low quality and limited quantity of safety reports, inadequate technical expertise, and insufficient tools for signal detection. These issues were further compounded by institutional constraints such as workforce shortages, weak coordination, and competing priorities, as well as broader systemic barriers including limited funding, weak governance, regulatory gaps, and suboptimal stakeholder engagement. Collectively, these factors impede the effective detection, analysis, and communication of medicine safety information.Interpretation: Sustainable improvement in PV requires coordinated investments in capacity, governance, funding, and collaboration. Isolated efforts are insufficient, and lasting progress depends on strong political commitment, national ownership, and continued advocacy. Isolated efforts, such as training without adequate funding or reliance on expert committees without structured processes and political backing, are unlikely to produce lasting improvements.
- 13 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBarriers and Facilitators of Signal Detection in African Pharmacovigilance Centres: Insights from a Multi-Country Qualitative Study
Background: Signal detection within African pharmacovigilance systems has faced multiple challenges. The contextual factors influencing signal detection and management remain underexplored. This study aimed to investigate and better understand the determinants that facilitate or hinder these processes across African pharmacovigilance systems.Methods: An explanatory qualitative design was employed, using in-depth interviews with representatives from selected National Pharmacovigilance(PV) Centers in Africa. A framework thematic analysis approach was applied to the data and synthesized using NVivo® 15 software.Findings: Twelve participants were included in the study. The framework thematic analysis generated three main themes and 13 subthemes related to signal detection and management in the African context. Major challenges included the low quality and limited quantity of safety reports, inadequate technical expertise, and insufficient tools for signal detection. These issues were further compounded by institutional constraints such as workforce shortages, weak coordination, and competing priorities, as well as broader systemic barriers including limited funding, weak governance, regulatory gaps, and suboptimal stakeholder engagement. Collectively, these factors impede the effective detection, analysis, and communication of medicine safety information.Interpretation: Sustainable improvement in PV requires coordinated investments in capacity, governance, funding, and collaboration. Isolated efforts are insufficient, and lasting progress depends on strong political commitment, national ownership, and continued advocacy. Isolated efforts, such as training without adequate funding or reliance on expert committees without structured processes and political backing, are unlikely to produce lasting improvements.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Patterns of adverse drug reactions in patients with drug resistant tuberculosis in Eswatini : a retrospective cohort study
Effets indésirables des médicaments de la tuberculose pharmaco-résistante en Eswatini et comparaison des caractéristiques des EI avec la base de données mondiale de pharmacovigilance : études prospectives et rétrospectives: La tuberculose multirésistante (TB-MR) constitue un problème de santé publique important, en particulier dans les pays en développement comme l'Eswatini. Le traitement de la TB-MR nécessite la combinaison de plusieurs médicaments pendant plusieurs mois, ce qui peut entraîner des réactions indésirables médicamenteuses (ADR). L'objectif de cette thèse était de caractériser et de décrire une analyse complète des profils de sécurité des médicaments contre la tuberculose multirésistante utilisés dans le traitement de la TB-MR au niveau mondial et national. Tout d'abord, nous avons évalué l'ampleur et les caractéristiques des réactions indésirables médicamenteuses liées à la TB-MR grâce à une analyse des rapports de la base de données (VigiBase) de l'Organisation mondiale de la santé (OMS). Nous avons ensuite étudié les caractéristiques des ADR chez les patients atteints de TB-MR dans tous les sites de traitement du Royaume de l'Eswatini. Enfin, nous avons réalisé une analyse des ADR associées à l'utilisation de la clofazimine (CFZ) et de la linézolide (LZD) dans une étude de cohorte prospective. L'analyse des rapports de sécurité individuels (ICSR) provenant de la VigiBase a montré que la pyrazinamide était le médicament le plus souvent associé aux ADR, suivie de l'éthionamide et de la cyclosérine. L'étude a révélé que près de la moitié des rapports nécessitaient le retrait complet du ou des médicaments suspectés, ce qui a un impact sur l'observance du traitement et conduit finalement à la résistance aux médicaments. L'étude de cohorte rétrospective a analysé les profils des ADR chez 670 patients atteints de TB-MR en Eswatini. Les résultats ont montré que 44% des patients avaient au moins une réaction indésirable médicamenteuse (ADR), le bédaquiline étant associé au plus grand nombre d'ADR. L'étude a révélé que l'âge est un facteur significatif dans l'apparition des réactions indésirables médicamenteuses (ADR) liées à la neuropathie périphérique et à l'arthralgie. L'analyse de cet échantillon a montré que près de la moitié des patients présentaient au moins une réaction indésirable médicamenteuse, et que près d'un tiers d'entre eux étaient graves. L'étude souligne l'importance de renforcer la surveillance de la sécurité des patients traités pour la TB-MR pour garantir une gestion rapide et appropriée des ADR, réduisant ainsi le risque d'échec du traitement. Les résultats de l'étude de cohorte prospective ont montré que 80% des patients traités par CFZ ou LZD ont développé des ADR. La CFZ était associée principalement à des ADR légers, tandis que la LZD était associée à des ADR plus graves, notamment l’anémie, neuropathie périphérique et la neurite optique. Cette thèse contribue à la compréhension des profils d'innocuité des médicaments contre la tuberculose pharmacorésistante dans différents contextes. Les études soulignent l'importance de surveiller de près les effets indésirables liés à ces médicaments tout au long de la durée du traitement afin de garantir la sécurité des patients et des résultats positifs du traitement. Les effets indésirables des médicaments, qu'ils soient directement liés aux médicaments ou non, peuvent entraîner une faible observance du traitement et l'arrêt du traitement. De tels résultats peuvent compromettre davantage l'efficacité du schéma thérapeutique, conduisant à l'éradication incomplète de la bactérie et à la résistance aux médicaments. Par conséquent, il est essentiel de surveiller l'innocuité des médicaments contre la tuberculose pharmacorésistante pour assurer la prise en charge des effets indésirables, réduisant ainsi le risque d'échec du traitement. Comprendre l'impact des effets indésirables et prendre des mesures proactives pour y faire face contribuera à des résultats thérapeutiques plus favorables et facilitera l'éradication complète de la tuberculose pharmacorésistante.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Patterns of adverse drug reactions in patients with drug resistant tuberculosis in Eswatini : a retrospective cohort study
Effets indésirables des médicaments de la tuberculose pharmaco-résistante en Eswatini et comparaison des caractéristiques des EI avec la base de données mondiale de pharmacovigilance : études prospectives et rétrospectives: La tuberculose multirésistante (TB-MR) constitue un problème de santé publique important, en particulier dans les pays en développement comme l'Eswatini. Le traitement de la TB-MR nécessite la combinaison de plusieurs médicaments pendant plusieurs mois, ce qui peut entraîner des réactions indésirables médicamenteuses (ADR). L'objectif de cette thèse était de caractériser et de décrire une analyse complète des profils de sécurité des médicaments contre la tuberculose multirésistante utilisés dans le traitement de la TB-MR au niveau mondial et national. Tout d'abord, nous avons évalué l'ampleur et les caractéristiques des réactions indésirables médicamenteuses liées à la TB-MR grâce à une analyse des rapports de la base de données (VigiBase) de l'Organisation mondiale de la santé (OMS). Nous avons ensuite étudié les caractéristiques des ADR chez les patients atteints de TB-MR dans tous les sites de traitement du Royaume de l'Eswatini. Enfin, nous avons réalisé une analyse des ADR associées à l'utilisation de la clofazimine (CFZ) et de la linézolide (LZD) dans une étude de cohorte prospective. L'analyse des rapports de sécurité individuels (ICSR) provenant de la VigiBase a montré que la pyrazinamide était le médicament le plus souvent associé aux ADR, suivie de l'éthionamide et de la cyclosérine. L'étude a révélé que près de la moitié des rapports nécessitaient le retrait complet du ou des médicaments suspectés, ce qui a un impact sur l'observance du traitement et conduit finalement à la résistance aux médicaments. L'étude de cohorte rétrospective a analysé les profils des ADR chez 670 patients atteints de TB-MR en Eswatini. Les résultats ont montré que 44% des patients avaient au moins une réaction indésirable médicamenteuse (ADR), le bédaquiline étant associé au plus grand nombre d'ADR. L'étude a révélé que l'âge est un facteur significatif dans l'apparition des réactions indésirables médicamenteuses (ADR) liées à la neuropathie périphérique et à l'arthralgie. L'analyse de cet échantillon a montré que près de la moitié des patients présentaient au moins une réaction indésirable médicamenteuse, et que près d'un tiers d'entre eux étaient graves. L'étude souligne l'importance de renforcer la surveillance de la sécurité des patients traités pour la TB-MR pour garantir une gestion rapide et appropriée des ADR, réduisant ainsi le risque d'échec du traitement. Les résultats de l'étude de cohorte prospective ont montré que 80% des patients traités par CFZ ou LZD ont développé des ADR. La CFZ était associée principalement à des ADR légers, tandis que la LZD était associée à des ADR plus graves, notamment l’anémie, neuropathie périphérique et la neurite optique. Cette thèse contribue à la compréhension des profils d'innocuité des médicaments contre la tuberculose pharmacorésistante dans différents contextes. Les études soulignent l'importance de surveiller de près les effets indésirables liés à ces médicaments tout au long de la durée du traitement afin de garantir la sécurité des patients et des résultats positifs du traitement. Les effets indésirables des médicaments, qu'ils soient directement liés aux médicaments ou non, peuvent entraîner une faible observance du traitement et l'arrêt du traitement. De tels résultats peuvent compromettre davantage l'efficacité du schéma thérapeutique, conduisant à l'éradication incomplète de la bactérie et à la résistance aux médicaments. Par conséquent, il est essentiel de surveiller l'innocuité des médicaments contre la tuberculose pharmacorésistante pour assurer la prise en charge des effets indésirables, réduisant ainsi le risque d'échec du traitement. Comprendre l'impact des effets indésirables et prendre des mesures proactives pour y faire face contribuera à des résultats thérapeutiques plus favorables et facilitera l'éradication complète de la tuberculose pharmacorésistante.
- Open Access
Strengthening National Regulatory Authorities in Africa: A Critical Step Towards Enhancing Local Manufacturing of Vaccines and Health Products
The World Health Organization (WHO) Global Benchmarking Tool (GBT) classifies regulatory systems into four maturity levels, with Maturity Level 3 (ML3) signifying a stable and effective regulatory environment. As of January 2025, eight African nations—Egypt, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania, and Zimbabwe—have attained ML3 status, marking a significant milestone in the continent’s regulatory landscape. Achieving ML3 confers critical benefits, including reducing substandard and falsified medicines, which enhances public health safety and fosters trust in healthcare systems. This progress encourages local manufacturing, diminishing reliance on imported medicines and promoting economic development. Furthermore, ML3 NRAs are better equipped to address public health emergencies, enabling swift approvals for vaccines and therapeutics while upholding safety standards. Nonetheless, challenges persist, including fragmented regulatory systems, the prevalence of counterfeit medicines, and limited resources. Overcoming these hurdles necessitates enhanced organizational capacity, investments in training, and the promotion of collaboration among NRAs. There is an urgent call for greater political commitment and resource allocation to strengthen regulatory systems across Africa. Achieving and maintaining ML3 status is essential for enhancing medicine regulation, supporting local manufacturing, and improving public health outcomes across the continent. While progress has been made, sustained efforts are crucial to tackling existing challenges and harnessing the full potential of advanced regulatory frameworks.
Open AccessStrengthening National Regulatory Authorities in Africa: A Critical Step Towards Enhancing Local Manufacturing of Vaccines and Health Products
The World Health Organization (WHO) Global Benchmarking Tool (GBT) classifies regulatory systems into four maturity levels, with Maturity Level 3 (ML3) signifying a stable and effective regulatory environment. As of January 2025, eight African nations—Egypt, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania, and Zimbabwe—have attained ML3 status, marking a significant milestone in the continent’s regulatory landscape. Achieving ML3 confers critical benefits, including reducing substandard and falsified medicines, which enhances public health safety and fosters trust in healthcare systems. This progress encourages local manufacturing, diminishing reliance on imported medicines and promoting economic development. Furthermore, ML3 NRAs are better equipped to address public health emergencies, enabling swift approvals for vaccines and therapeutics while upholding safety standards. Nonetheless, challenges persist, including fragmented regulatory systems, the prevalence of counterfeit medicines, and limited resources. Overcoming these hurdles necessitates enhanced organizational capacity, investments in training, and the promotion of collaboration among NRAs. There is an urgent call for greater political commitment and resource allocation to strengthen regulatory systems across Africa. Achieving and maintaining ML3 status is essential for enhancing medicine regulation, supporting local manufacturing, and improving public health outcomes across the continent. While progress has been made, sustained efforts are crucial to tackling existing challenges and harnessing the full potential of advanced regulatory frameworks.
- 3 January 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (2) , 362-363
Resurgence of malaria and artemisinin resistance in Africa requires a concerted response
- 3 January 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (2) , 362-363
Resurgence of malaria and artemisinin resistance in Africa requires a concerted response
- Open Access
- 1 January 2025
- Published by AOSIS in Journal of Public Health in Africa
- Vol. 16 (1) , 4
Diethylene glycol: Unnoticed threat in the landscape of fixed-dose combination medications
Diethylene glycol (DEG) and ethylene glycol (EG) are organic compounds often found in various consumer products, including antifreeze and industrial solvents used in pharmaceutical preparations, as well as serving as raw materials for polymer manufacturing. Since September 2022, seven consecutive episodes of DEG and EG contamination have been reported across at least nine countries. A notable commonality among the affected products is that at least 14 of them are fixed-dose combinations (FDCs). However, the evidence supporting the efficacy of most of these combinations is insufficient, which renders their prescription, dispensing, and use irrational. Moreover, these products are not without risk, as they can cause adverse reactions. Several factors contribute to the prevalence of these irrational FDCs, including low production costs, consumer popularity, and a tendency to authorise locally manufactured products. As a result, many countries’ pharmaceutical markets keep marketing authorisation for irrational FDCs. The persistent reports of DEG or EG contamination – especially those involving irrational fixed-dose combinations – present a crucial opportunity to enhance quality control measures. In addition, it is imperative to reevaluate the marketing authorisations of these products that lack evidence of safety and efficacy, adapting the national medicines lists and clinical guidelines to WHO recommendations. Strengthening regulatory frameworks and implementing stringent manufacturing and quality assurance standards are essential to prevent contamination incidents and ensure the safety of pharmaceutical products.
- 1 January 2025
- Published by AOSIS in Journal of Public Health in Africa
- Vol. 16 (1) , 4
Open AccessDiethylene glycol: Unnoticed threat in the landscape of fixed-dose combination medications
Diethylene glycol (DEG) and ethylene glycol (EG) are organic compounds often found in various consumer products, including antifreeze and industrial solvents used in pharmaceutical preparations, as well as serving as raw materials for polymer manufacturing. Since September 2022, seven consecutive episodes of DEG and EG contamination have been reported across at least nine countries. A notable commonality among the affected products is that at least 14 of them are fixed-dose combinations (FDCs). However, the evidence supporting the efficacy of most of these combinations is insufficient, which renders their prescription, dispensing, and use irrational. Moreover, these products are not without risk, as they can cause adverse reactions. Several factors contribute to the prevalence of these irrational FDCs, including low production costs, consumer popularity, and a tendency to authorise locally manufactured products. As a result, many countries’ pharmaceutical markets keep marketing authorisation for irrational FDCs. The persistent reports of DEG or EG contamination – especially those involving irrational fixed-dose combinations – present a crucial opportunity to enhance quality control measures. In addition, it is imperative to reevaluate the marketing authorisations of these products that lack evidence of safety and efficacy, adapting the national medicines lists and clinical guidelines to WHO recommendations. Strengthening regulatory frameworks and implementing stringent manufacturing and quality assurance standards are essential to prevent contamination incidents and ensure the safety of pharmaceutical products.
- Open Access
- 9 October 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (10) , e015445
Malaria vaccine rollout begins in Africa: the need to strengthen regulatory and safety surveillance systems in Africa
- 9 October 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (10) , e015445
Open AccessMalaria vaccine rollout begins in Africa: the need to strengthen regulatory and safety surveillance systems in Africa
- 22 August 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (10) , 2706-2707
A community engagement framework to accelerate the uptake of malaria vaccines in Africa
- 22 August 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (10) , 2706-2707
A community engagement framework to accelerate the uptake of malaria vaccines in Africa